Quarterly report · Q2
4544.TEDINET S100PJXC
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥134.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥133.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥17.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥27.0bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.7bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥25.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥19.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥285.9bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥271.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥128.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥157.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥130.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥37.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥37.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥41.8bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥15.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥273.42 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.17 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥342.23 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.93 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥273.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥342.1 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥85.1bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥85.0bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥83m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥40.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥15.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥604m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥139.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥134.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥4.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥746m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥33m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥138.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥133.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.9bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥27.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 532
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 10000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 5085000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -5085000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 85123000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 40216000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 13827000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 139167000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -5085000000 | JPY |
| Net sales | CurrentYTDDuration | 134081000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 2932000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 15694000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 604000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 19231000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -1546000000 | JPY |
| Operating income | CurrentYTDDuration | 17684000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-11 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第73期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)H.U.グループホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | H.U. Group Holdings, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役 代表執行役社長 兼 グループCEO 竹内 成和 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都新宿区西新宿二丁目１番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)０３（５９０９）３３３５（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役 兼 CFO 村上 敦子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都新宿区西新宿二丁目１番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０３（５９０９）３３３７ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役 兼 CFO 村上 敦子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00967 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45440 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)H.U.グループホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | H.U. Group Holdings, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-09-30 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |